Company intelligence / Profile preview
Trust Bio-sonics Inc.
Taiwantrust-biosonics.com ↗
- Ownership
- Private
- Employees
- ~12
- Development stage
- Phase 3
01
Overview
Leading candidate TBS-002 (ultrasound enhancing agent) has received Phase 3 trial approval from both USFDA and Taiwan FDA. Pre-clinical studies completed for pancreatic cancer treatment with significant therapeutic results.
- Therapeutic areas
- OncologyCardiovascular
- Modalities
- Microsphere technologiesMicrobubble formulationsUltrasound-mediated drug delivery
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Scintica (exclusive distribution agreement for North America and Europe)National Taiwan University Hospital (clinical translation)
Beyond the preview
Go deeper on Trust Bio-sonics Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trust Bio-sonics Inc..